Rolapitant has 8 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Pimozide, Thioridazine, Dextromethorphan. Patients taking Rolapitant should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Contraindicated
- 2
- Moderate
- 5
Contraindicated (2)
- Rolapitant + Pimozide— Increased plasma concentrations associated with serious and life-threatening QT prolongation and Torsades de Pointes.
- Rolapitant + Thioridazine— Increased plasma concentrations associated with serious and life-threatening QT prolongation and Torsades de Pointes.
Moderate (5)
- Rolapitant + Dextromethorphan— 2.3-fold increase in plasma concentrations with inhibitory effect persisting beyond 28 days.
- Rolapitant + Digoxin— Increased plasma concentrations may result in potential adverse reactions.
- Rolapitant + Irinotecan— Increased plasma concentrations may result in potential adverse reactions. Monitor for adverse reactions if use cannot b…
- Rolapitant + Methotrexate— Increased plasma concentrations may result in potential adverse reactions. Monitor for adverse reactions if use cannot b…
- Rolapitant + Topotecan— Increased plasma concentrations may result in potential adverse reactions. Monitor for adverse reactions if use cannot b…